AI Can Accelerate Search for More Effective Alzheimer’s Medicines

Scientists have used an AI model to reassess the results of a completed clinical trial for an Alzheimer’s disease drug. They found the drug slowed cognitive decline by 46% in a group of patients with early stage, slow-progressing mild cognitive impairment – a condition that can progress to Alzheimer’s. The AI model developed by researchers at the University of Cambridge predicts whether, and how quickly, people at early stages of cognitive decline will progress to full-blown Alzheimer’s